128 related articles for article (PubMed ID: 20097148)
21. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
22. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
[TBL] [Abstract][Full Text] [Related]
23. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study.
Bommer J; Asmus G; Wenning M; Bommer G
Nephrol Dial Transplant; 2008 Dec; 23(12):4002-8. PubMed ID: 18676350
[TBL] [Abstract][Full Text] [Related]
24. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis].
Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E
Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567
[TBL] [Abstract][Full Text] [Related]
25. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
[TBL] [Abstract][Full Text] [Related]
26. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
Papatheofanis FJ; McKenzie RS; Mody SH; Suruki RY; Piech CT
Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
[TBL] [Abstract][Full Text] [Related]
27. [Feasibility strategy of darbepoetin alfa administration every other week: 2005-2007 experience in a dialysis unit].
Rottembourg JB; Dansaert A
Nephrol Ther; 2011 Dec; 7(7):549-57. PubMed ID: 21622039
[TBL] [Abstract][Full Text] [Related]
28. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.
Raymond CB; Wazny LD; Vercaigne LM; Lesperance EM; Skwarchuk DE; Bernstein KN
CANNT J; 2008; 18(1):39-43. PubMed ID: 18435363
[TBL] [Abstract][Full Text] [Related]
29. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
Pussell BA; Walker R;
Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
[TBL] [Abstract][Full Text] [Related]
30. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
31. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
Sharma A; Yee J; Gandra SR; Khan I; Petersen J
Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
[TBL] [Abstract][Full Text] [Related]
32. [Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule].
Borget I; Chouaid C; Demarteau N; Annemans L; Pujol JL
Bull Cancer; 2008 Apr; 95(4):465-73. PubMed ID: 18495577
[TBL] [Abstract][Full Text] [Related]
33. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
[TBL] [Abstract][Full Text] [Related]
34. Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients.
Churchill DN; Macarios D; Attard C; Kallich J; Goeree R
Nephron Clin Pract; 2007; 106(4):c193-8. PubMed ID: 17596729
[TBL] [Abstract][Full Text] [Related]
35. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
36. [Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?].
Borrelli S; Baldanza D; Scigliano R; Catapano F; Grimaldi M; Calabria M; Zamboli P; Minutolo R; De Nicola L; Conte G
G Ital Nefrol; 2009; 26(1):31-7. PubMed ID: 19255962
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
[TBL] [Abstract][Full Text] [Related]
38. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Lafeuille MH; Bailey RA; Vekeman F; Scott McKenzie R; Lefebvre P
J Med Econ; 2012; 15(2):352-60. PubMed ID: 22168787
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
40. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
